Table 1.
Patient characteristics, treatment status and predictors of ART initiation in HIV+ pregnant women under PMTCTB+
| Characteristics at ANC1 | Treatment status | Predictors of treatment initiation | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Eligible for ART, n (%) | Initiated ART, n (%) | Switched from AZT to ART, n (%) | AZT, n (%) | No AZT/ ART, n (%) | cHR (95% CI) | p | aHR (95% CI) (n = 665) |
p | |
| Total (n = 665) | 665 | 496 | 47 | 70 | 99 | ||||
| CD4 | |||||||||
| 0–349 | 260 (39.1) | 224 (45.2) | 21 (44.7) | 14 (20.0) | 22 (22.2) | Reference | Reference | ||
| 350–499 | 171 (25.7) | 132 (26.6) | 14 (29.8) | 20 (28.6) | 19 (19.2) | 0.77 (0.62,0.95) | 0.015 | 0.82 (0.66,1.02) | 0.075 |
| ≥500 | 170 (25.6) | 119 (24) | 11 (23.4) | 24 (34.3) | 27 (27.3) | 0.66 (0.53,0.83) | < 0.001 | 0.69 (0.56, 0.87) | 0.002 |
| Missing | 64 (9.6) | 21 (4.2) | 1 (2.1) | 12 (17.1) | 31 (31.3) | 0.23 (0.14,0.35) | < 0.001 | 0.31 (0.20,0.49) | < 0.001 |
| WHO | |||||||||
| I + II | 506 (76.1) | 416 (83.9) | 44 (93.6) | 42 (60.0) | 48 (48.5) | Reference | Reference | ||
| III + IV | 15 (2.3) | 11 (2.2) | 1 (2.1) | 3 (4.3) | 1 (1.0) | 0.78 (0.43,1.42) | 0.418 | 0.78 (0.43,1.42) | 0.418 |
| Missing | 144 (21.7) | 69 (13.9) | 2 (4.3) | 25 (35.7) | 50 (50.5) | 0.43 (0.33,0.55) | < 0.001 | 0.40 (0.31,0.52) | < 0.001 |
| Agegroup (n = 662) | |||||||||
| 16–24 | 271 (40.8) | 197 (39.7) | 24 (51.1) | 33 (47.1) | 41 (41.4) | Reference | |||
| 25–34 | 344 (51.7) | 260 (52.4) | 22 (46.8) | 34 (48.6) | 50 (50.5) | 1.11 (0.92, 1.33) | 0.284 | ||
| ≥35 | 47 (7.1) | 38 (7.7) | 1 (2.1) | 2 (2.9) | 7 (7.1) | 1.26 (0.89,1.79) | 0.190 | ||
| HIV diagnosis (n = 658) | |||||||||
| New | 408 (61.4) | 307 (61.9) | 32 (68.1) | 47 (67.1) | 54 (54.5) | Reference | |||
| Previously diagnosed | 250 (37.6) | 185 (37.3) | 15 (31.9) | 22 (31.4) | 43 (43.4) | 1.01 (0.84,1.21) | 0.920 | ||
| Trimester (n = 588) | |||||||||
| 1st | 64 (9.6) | 50 (10.1) | 2 (4.3) | 7 (10.0) | 7 (7.1) | Reference | |||
| 2nd | 413 (62.1) | 318 (64.1) | 34 (72.3) | 46 (65.7) | 49 (49.5) | 0.93 (0.69,1.25) | 0.635 | ||
| 3rd | 111 (16.7) | 82 (16.5) | 6 (12.8) | 10 (14.3) | 19 (19.2) | 0.91 (0.64,1.29) | 0.599 | ||
| Pregnancy (n = 661) | |||||||||
| 1st | 131 (19.7) | 100 (20.2) | 15 (31.9) | 14 (20) | 17 (17.2) | Reference | |||
| ≥2nd | 530 (79.7) | 394 (79.4) | 32 (68.1) | 55 (78.6) | 81 (81.8) | 0.97 (0.78,1.21) | 0.805 | ||
| Health care facility (n = 665) | |||||||||
| Primary | 354 (53.2) | 253 (51) | 15 (31.9) | 43 (61.4) | 58 (58.6) | Reference | Reference | ||
| Secondary | 311 (46.8) | 243 (49) | 32 (68.1) | 27 (38.6) | 41 (41.4) | 1.16 (0.97,1.38) | 0.099 | 1.15(0.96,1.37) | 0.132 |
| Enrolment phasea | |||||||||
| Early | 232 (34.9) | 150 (30.2) | 32 (68.1) | 43 (61.4) | 39 (39.4) | Reference | Reference | ||
| Mid | 202 (30.4) | 148 (29.8) | 12 (25.5) | 22 (31.4) | 32 (32.3) | 1.37 (1.09,1.72) | 0.007 | 1.41 (1.12,1.77) | 0.003 |
| Late | 231 (34.7) | 198 (39.9) | 3 (6.4) | 5 (7.1) | 28 (28.3) | 2.17 (1.75,2.70) | 0.000 | 2.36 (1.89,2.94) | < 0.001 |
cHR crude hazard ratio, aHR adjusted hazard ratio
aDefinition of study enrolment phases: early from 01/2013 to 06/2013, mid from 07/2013 to 12/2013 and late from 01/2014 to 06/2014